Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sang Nae Cho

Showing results (171-180 of 178) with videos related to

Pageof 18
Sort By:
You have reached the last page of results.This site can display upto 178 results.
Lancet (London, England)|December 15, 2022
9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in South KoreaJeongha Mok, Myungsun Lee, Deog Kyeom Kim, et al.
Trials|January 18, 2019
Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trialMyungsun Lee, Jeongha Mok, Deog Kyeom Kim, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 25, 2014
Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosisJ Peter Cegielski, Tracy Dalton, Martin Yagui, et al.
Nature Genetics|January 17, 2017
Genomic analysis of globally diverse Mycobacterium tuberculosis strains provides insights into the emergence and spread of multidrug resistanceAbigail L Manson, Keira A Cohen, Thomas Abeel, et al.
Nature Medicine|August 6, 2013
Discovery of Q203, a potent clinical candidate for the treatment of tuberculosisKevin Pethe, Pablo Bifani, Jichan Jang, et al.
Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases|May 17, 2011
European 1: a globally important clonal complex of Mycobacterium bovisNoel H Smith, Stefan Berg, James Dale, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 29, 2015
Multidrug-Resistant Tuberculosis Treatment Outcomes in Relation to Treatment and Initial Versus Acquired Second-Line Drug ResistanceJ Peter Cegielski, Ekaterina Kurbatova, Martie van der Walt, et al.
Lancet (London, England)|September 4, 2012
Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort studyTracy Dalton, Peter Cegielski, Somsak Akksilp, et al.
Pageof 18

Showing results (171-180 of 178) with videos related to

Sort By:
Pageof 18
You have reached the last page of results.This site can display upto 178 results.
Lancet (London, England)|December 15, 2022
9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in South KoreaJeongha Mok, Myungsun Lee, Deog Kyeom Kim, et al.
Trials|January 18, 2019
Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trialMyungsun Lee, Jeongha Mok, Deog Kyeom Kim, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 25, 2014
Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosisJ Peter Cegielski, Tracy Dalton, Martin Yagui, et al.
Nature Genetics|January 17, 2017
Genomic analysis of globally diverse Mycobacterium tuberculosis strains provides insights into the emergence and spread of multidrug resistanceAbigail L Manson, Keira A Cohen, Thomas Abeel, et al.
Nature Medicine|August 6, 2013
Discovery of Q203, a potent clinical candidate for the treatment of tuberculosisKevin Pethe, Pablo Bifani, Jichan Jang, et al.
Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases|May 17, 2011
European 1: a globally important clonal complex of Mycobacterium bovisNoel H Smith, Stefan Berg, James Dale, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 29, 2015
Multidrug-Resistant Tuberculosis Treatment Outcomes in Relation to Treatment and Initial Versus Acquired Second-Line Drug ResistanceJ Peter Cegielski, Ekaterina Kurbatova, Martie van der Walt, et al.
Lancet (London, England)|September 4, 2012
Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort studyTracy Dalton, Peter Cegielski, Somsak Akksilp, et al.
Pageof 18